|
|||||
|
|
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen |
|
| Authors: | Booth Christopher M Pater Joseph L Goss Paul E |
| Affiliation: | 1. National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada;2. Massachusetts General Hospital Cancer Center, Boston, Massachusetts;3. Paul E. Goss receives honoraria and is on the advisory boards of Novartis, Pfizer, Astra‐Zeneca, and Glaxo Smith Kline pharmaceutical companies. |
| Abstract: | |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ | |